SARS-CoV-2 recombinant protein vaccine Formulation 1

SARS-CoV-2 recombinant protein vaccine Formulation 1 refers to a specific experimental preparation of a protein subunit vaccine designed to prevent COVID-19. This formulation typically consists of a recombinant version of the SARS-CoV-2 spike (S) protein, or a fragment such as the Receptor Binding Domain (RBD), produced in a specialized expression system (such as insect cells via baculovirus or mammalian cells). Recombinant protein vaccines work by presenting the viral antigen directly to the immune system to elicit neutralizing antibodies and T-cell responses. Because purified proteins are often poorly immunogenic on their own, such formulations are usually combined with a specific adjuvant system to enhance the magnitude and durability of the immune response. The designation Formulation 1 is typically used in dose-ranging or adjuvant-selection Phase 1/2 clinical trials to distinguish it from alternative preparations (Formulation 2, etc.) that may vary in antigen concentration, adjuvant type, or buffer composition.

Other names

SARS-CoV-2 recombinant protein vaccine Formulation 1SARS-CoV2 recombinant protein vaccine Formulation 1SARS-CoV 2 recombinant protein vaccine Formulation 1